Ace Therapeutics, a specialized contract research organization (CRO) focused on translational blood disorder research, has announced the launch of a full-scale suite of integrated preclinical hematology CRO services. The offering is designed to accelerate the discovery and regulatory advancement of novel therapeutics for a broad spectrum of hematologic diseases, including inherited anemias, autoimmune blood conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders.
The company’s expanded services address common bottlenecks in traditional preclinical research, such as limited model translatability and lack of end-to-end study execution. By providing vertically integrated services that unify in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics, Ace Therapeutics aims to support biotech and pharmaceutical developers advancing gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments for blood disorders.
Central to the announcement is the company’s robust collection of in vivo hematologic disease models. These models are built across multiple preclinical species, including mice, rats, dogs, and non-human primates, to accommodate diverse research objectives. The categorized model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft (PDX) constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, the preclinical hematology CRO services deliver cutting-edge in vitro modeling platforms. These include biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays utilizing primary human CD34+ hematopoietic stem and progenitor cells sourced from bone marrow, cord blood, and mobilized peripheral blood.
The services extend across the full drug development lifecycle, from target identification and CRISPR-based target validation to specialized PK/PD profiling tailored to blood disorder therapeutics. Hematology-focused safety pharmacology and toxicology assessments help evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues including the spleen and bone marrow. Specialized technical support is also offered for all therapeutic modalities, ranging from small-molecule iron chelators and JAK inhibitors to monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients seeking customized research programs can collaborate with Ace Therapeutics to design tailored study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions.
For leaders in business and technology, this announcement signals a significant advancement in the infrastructure available for blood disorder drug development. By addressing key translational gaps, Ace Therapeutics’ services could reduce development timelines and costs for therapies targeting a range of hematologic diseases, potentially accelerating the availability of new treatments for patients.
